marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2024
added 10-25-2025
Oncolytics Biotech Market Cap 2011-2025 | ONCY
As of November 02, 2025 Oncolytics Biotech has a market cap of $ 115 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Oncolytics Biotech
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 74.4 M | 52.7 M | 105 M | 29 M | 75.5 M | 24 M | 30.4 M | 36.9 M | 138 M | 274 M | 327 M |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 327 M | 24 M | 106 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Graybug Vision
GRAY
|
1.97 M | $ 0.44 | -11.23 % | $ 9.65 M |  USA |
 |
AgeX Therapeutics
AGE
|
14.1 K | $ 11.3 | -10.17 % | $ 12.2 K | - |
 |
Galera Therapeutics
GRTX
|
7.65 M | $ 0.14 | -32.59 % | $ 7.61 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
167 M | $ 4.37 | -1.58 % | $ 28.1 M |  China |
 |
Axon Enterprise
AXON
|
39.8 B | $ 755.0 | 0.8 % | $ 57.2 B | USA |
 |
Caladrius Biosciences
CLBS
|
3.58 M | $ 0.43 | -16.75 % | $ 25.8 M | USA |
 |
Sorrento Therapeutics
SRNE
|
590 M | $ 0.27 | -29.58 % | $ 126 M | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | $ 184.71 | 0.49 % | $ 251 B |  Cayman-islands |
 |
Kamada Ltd.
KMDA
|
271 M | $ 6.95 | -1.56 % | $ 260 M |  Israel |
 |
ContraFect Corporation
CFRX
|
1.08 M | $ 1.47 | -5.16 % | $ 5.39 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
672 M | $ 4.93 | 1.02 % | $ 90.8 M |  Britain |
 |
Midatech Pharma plc
MTP
|
79 M | $ 0.29 | -18.52 % | $ 27.3 M | Britain |
 |
Advaxis
ADXS
|
1.87 M | $ 0.31 | -9.65 % | $ 45.9 M | USA |
 |
Heat Biologics, Inc.
HTBX
|
32.8 M | $ 3.93 | -5.76 % | $ 99.8 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
110 M | $ 6.2 | - | $ 154 M | USA |
 |
Zymeworks
ZYME
|
845 M | $ 6.42 | - | $ 404 M |  Canada |
 |
Aeterna Zentaris
AEZS
|
41.4 M | $ 5.72 | 5.93 % | $ 314 M | Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
52.7 M | $ 10.5 | - | $ 231 M | USA |
 |
Kadmon Holdings, Inc.
KDMN
|
813 M | $ 9.5 | - | $ 1.7 B | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | $ 2.58 | -4.8 % | $ 255 M | USA |
 |
Mesoblast Limited
MESO
|
1.3 B | $ 16.73 | 0.12 % | $ 10.9 B |  Australia |
 |
Zosano Pharma Corporation
ZSAN
|
52.7 M | $ 0.56 | 7.23 % | $ 2.72 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | $ 0.5 | - | $ 7.46 M | Israel |
 |
Kiromic BioPharma
KRBP
|
4.83 M | $ 3.15 | 6.61 % | $ 3.08 M | USA |
 |
Acceleron Pharma Inc.
XLRN
|
6.89 B | $ 179.68 | - | $ 10.9 B | USA |
 |
Moderna
MRNA
|
13.5 B | $ 25.35 | -4.91 % | $ 9.73 B | USA |
 |
Albireo Pharma
ALBO
|
538 M | $ 44.15 | -0.23 % | $ 916 M | USA |
 |
Merus N.V.
MRUS
|
2.98 B | $ 94.9 | 0.32 % | $ 6.09 B |  Niderland |
 |
Stealth BioTherapeutics Corp
MITO
|
450 M | $ 0.32 | - | $ 23.9 M | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
1.1 B | $ 18.44 | - | $ 1.94 B | Canada |
 |
Kaleido Biosciences
KLDO
|
73.7 M | $ 0.29 | -3.69 % | $ 12.4 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
73.7 M | $ 2.19 | - | $ 105 M | USA |
 |
Humanigen
HGEN
|
12.5 M | $ 0.04 | -81.12 % | $ 4.28 M | USA |
 |
Aptinyx
APTX
|
9.48 M | $ 0.06 | -39.0 % | $ 4.57 M | USA |
 |
Tyme Technologies
TYME
|
186 M | $ 0.31 | 8.07 % | $ 54 M | USA |
 |
Forward Pharma A/S
FWP
|
584 M | $ 2.64 | -0.75 % | $ 18.7 M |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | $ 0.39 | - | $ 26.5 M | USA |
 |
Celyad Oncology SA
CYAD
|
41.7 M | $ 0.47 | - | $ 12.5 M |  Belgium |
 |
Nektar Therapeutics
NKTR
|
167 M | $ 60.92 | -2.64 % | $ 11.6 B | USA |
 |
Brickell Biotech
BBI
|
11.4 M | $ 2.11 | -5.38 % | $ 6.06 M | USA |
 |
Genocea Biosciences
GNCA
|
72.7 M | $ 0.05 | -15.0 % | $ 3.04 M | USA |
 |
Codiak BioSciences
CDAK
|
240 M | $ 0.06 | -55.98 % | $ 2.15 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
103 M | $ 8.37 | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | $ 3.17 | 1.93 % | $ 17.4 M | USA |
 |
Calithera Biosciences
CALA
|
960 M | $ 0.37 | -10.95 % | $ 876 K | USA |
 |
Ocular Therapeutix
OCUL
|
939 M | $ 11.53 | -0.17 % | $ 1.82 B | USA |
 |
Forma Therapeutics Holdings
FMTX
|
467 M | $ 20.01 | - | $ 958 M | USA |
 |
Oragenics
OGEN
|
3.24 M | $ 1.29 | -2.27 % | $ 2.9 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | $ 49.55 | -6.81 % | $ 3.04 B | USA |